Healthcare Services

An Important Factor Driving the Complicated Urinary Tract Infection Treatment Market Is the Rising Incidence Of Chronic Kidney Disease To Drive Growth In The Market

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Complicated Urinary Tract Infection Treatment Market Over The Period 2026–2030?

The complicated urinary tract infection treatment market size has experienced significant growth in recent years. This market is projected to expand from $9.44 billion in 2025 to $10.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been driven by an increasing prevalence of catheter associated infections, rising antibiotic resistance, the growth in the aging population, expanding hospital infrastructure, and a higher diagnosis rate for chronic urinary disorders.

The complicated urinary tract infection treatment market is projected to experience substantial growth in the upcoming years. By 2030, its size is expected to reach $12.74 billion, driven by a compound annual growth rate (CAGR) of 6.1%. This anticipated expansion over the forecast period stems from factors such as the development of novel antibiotics, an increasing base of immunocompromised patients, greater utilization of outpatient infusion therapies, rising healthcare expenditure, and enhanced pathogen identification technologies. Significant trends during this period include the optimization of empiric therapy, a growing reliance on broad-spectrum antibiotics, more hospitalizations for complicated UTIs, an evolving preference for combination drug therapies, and the broadening of hospital pharmacy-based dispensing services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21156&type=smp

Which Economic Or Industry Drivers Are Impacting The Complicated Urinary Tract Infection Treatment Market?

The increasing occurrence of chronic kidney diseases is projected to drive the growth of the complicated urinary tract infection treatment market in the coming years. Chronic kidney disease (CKD) is a long-term condition marked by a gradual decline in kidney function over time. The growing prevalence of chronic kidney disease (CKD) is primarily attributed to rising rates of diabetes and hypertension, along with aging populations and lifestyle factors such as obesity and smoking. Complicated urinary tract infection treatment provides support to chronic kidney disease (CKD) patients by preventing severe infections, such as pyelonephritis, which can worsen kidney damage, degrade renal function, and accelerate the progression of chronic kidney disease, ultimately decreasing the risk of further complications and hospitalizations. For instance, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, chronic kidney disease contributed 1.1% to the overall disease burden in Australia. Thus, the rising incidence of chronic kidney diseases is a key driver for the complicated urinary tract infection treatment market.

How Is The Complicated Urinary Tract Infection Treatment Market Divided Into Its Major Segments?

The complicated urinary tract infection treatment market covered in this report is segmented –

1) By Drug Class: Penicillin And Combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitro Furans

2) By Distribution Channel: Hospital Pharmacies, Gynecology And Urology Clinics, Drug Stores

3) By Application: Urethritis, Cystitis, Pyelonephritis

Subsegments:

1) By Penicillin And Combinations: Aminopenicillins, Beta-Lactamase Inhibitor Combinations

2) By Quinolones: Fluoroquinolones, Non-Fluoroquinolones

3) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins

4) By Azoles And Amphotericin B: Triazoles, Imidazoles, Polyene Antifungals

5) By Nitrofurans: Nitrofurantoin, Furazolidone

What Trends Are Affecting The Expansion Of The Complicated Urinary Tract Infection Treatment Market?

Leading firms in the complicated urinary tract infection treatment market are concentrating on developing innovative antibiotics to overcome antibiotic resistance, thereby improving treatment effectiveness and tackling evolving multidrug-resistant pathogens. Anti-infective approaches for complicated urinary tract infection treatment utilize specific antibiotics or antimicrobial agents to eradicate or manage infections, especially in critical situations where the kidneys are affected. As an illustration, in February 2024, the German biopharmaceutical company, Allecra Therapeutics, declared that its drug EXBLIFEP (cefepime/enmetazobactam) received U.S. Food and Drug Administration (FDA) approval for managing complicated urinary tract infections (cUTIs) in adults. Furthermore, the company obtained a five-year extension for marketing exclusivity, granted under the GAIN Act, which encourages the creation of novel anti-infective treatments. Research indicated that 79.1% of individuals who received cefepime/enmetazobactam exhibited a combined positive outcome (encompassing clinical cure and microbiological eradication), as opposed to 58.9% of patients treated with piperacillin/tazobactam.

Who Are The Prominent Organizations Shaping The Complicated Urinary Tract Infection Treatment Market?

Major companies operating in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

Read the full complicated urinary tract infection treatment market report here:

https://www.thebusinessresearchcompany.com/report/complicated-urinary-tract-infection-treatment-global-market-report

What Are The Top-Performing Regions Within The Complicated Urinary Tract Infection Treatment Market?

North America was the largest region in the complicated urinary tract infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complicated urinary tract infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Complicated Urinary Tract Infection Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21156&type=smp

Browse Through More Reports Similar to the Global Complicated Urinary Tract Infection Treatment Market 2026, By The Business Research Company

Botanicals And Acupuncture Global Market Report

https://www.thebusinessresearchcompany.com/report/botanicals-and-acupuncture-global-market-report

Herbal Medicine Global Market Report

https://www.thebusinessresearchcompany.com/report/herbal-medicine-global-market-report

Herbal Supplements Global Market Report

https://www.thebusinessresearchcompany.com/report/herbal-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795